Mylan and Hospira recall drugs after particulate discovered by Eric Palmer Tuesday, March 19, 2019 Mylan is recalling a chemo drug and Hospira a commonly used solution because potentially dangerous particulate has been discovered in vials.
FDA issues warning letter to India plant Pfizer is closing by Eric Palmer Wednesday, March 13, 2019 Pfizer is closing a Hospira plant in India, but the FDA still issued a warning letter for a list of serious violations it uncovered last year.
Pfizer offers ‘attractive’ severance package to Indian employees by Angus Liu Monday, January 14, 2019 Pfizer is offering some 1,700 door-heading employees "an attractive financial scheme that is significantly higher than the legal requirements."
Pfizer to cut 2 Hospira plants, 1,700 jobs in India by Angus Liu Wednesday, January 9, 2019 Pfizer's plan to close two legacy Hospira plants in India puts 1,700 jobs stationed there at risk.
Pfizer again supplying pain drugs to veterinarians by Eric Palmer Monday, December 17, 2018 The FDA’s Center for Veterinary Medicine has reached an agreement for Pfizer to divert part of a new source of injected pain drugs to veterinarians.
Issues persist at Pfizer's Hospira injectables plant by Eric Palmer Wednesday, December 12, 2018 The most recent inspection of Pfizer's troubled injectables plant in McPherson, Kansas, found eight observations, seven of them repeats.
Civica Rx, with support from 120 hospitals, to produce 14 drugs by Eric Palmer Thursday, September 6, 2018 A hospital-backed group, Civica Rx intends to manufacture or contract the production of 14 drugs that are in chronic supply.
FDA to observations after reinspection of troubled Hospira plant by Eric Palmer Monday, August 20, 2018 Pfizer says that its former Hospira plants that produces injected opioids for use in hospitals was reinspected this month by the FDA.
Pfizer halts production at troubled Indian injectables plant by Eric Palmer Tuesday, July 17, 2018 Pfizer has again suspended production at a long-troubled sterile injectables plant in India that the FDA has twice before cited.
Why another Pfizer reorg? Maybe—finally—a generics selloff by Angus Liu Wednesday, July 11, 2018 Pfizer’s latest overhaul sets biosimilars and hospital drugs alongside innovative products, where they can get brand-level attention.
